Journal article 225 views
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
Robert J. Motzer,
Bernard Escudier,
Saby George,
Hans J. Hammers,
Sandhya Srinivas,
Scott S. Tykodi,
Jeffrey A. Sosman,
Elizabeth R. Plimack,
Giuseppe Procopio,
David F. McDermott,
Daniel Castellano,
Toni K. Choueiri,
Frede Donskov,
Howard Gurney,
Stéphane Oudard,
Martin Richardet,
Katriina Peltola,
Ajjai S. Alva,
Michael Carducci,
John Wagstaff,
Christine Chevreau,
Satoshi Fukasawa,
Yoshihiko Tomita,
Thomas C. Gauler,
Christian K. Kollmannsberger,
Fabio A. Schutz,
James Larkin,
David Cella,
M. Brent McHenry,
Shruti Shally Saggi,
Nizar M. Tannir
Cancer, Volume: 126, Issue: 18, Pages: 4156 - 4167
Swansea University Author: John Wagstaff
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1002/cncr.33033
Abstract
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
| Published in: | Cancer |
|---|---|
| ISSN: | 0008-543X 1097-0142 |
| Published: |
Wiley
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa55409 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| first_indexed |
2020-11-11T16:48:35Z |
|---|---|
| last_indexed |
2020-11-12T04:14:05Z |
| id |
cronfa55409 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2020-11-11T16:48:39.1648073</datestamp><bib-version>v2</bib-version><id>55409</id><entry>2020-10-13</entry><title>Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-10-13</date><deptcode>SGMED</deptcode><abstract/><type>Journal Article</type><journal>Cancer</journal><volume>126</volume><journalNumber>18</journalNumber><paginationStart>4156</paginationStart><paginationEnd>4167</paginationEnd><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0008-543X</issnPrint><issnElectronic>1097-0142</issnElectronic><keywords/><publishedDay>15</publishedDay><publishedMonth>9</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-09-15</publishedDate><doi>10.1002/cncr.33033</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-11-11T16:48:39.1648073</lastEdited><Created>2020-10-13T12:21:45.2061165</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Robert J.</firstname><surname>Motzer</surname><order>1</order></author><author><firstname>Bernard</firstname><surname>Escudier</surname><order>2</order></author><author><firstname>Saby</firstname><surname>George</surname><order>3</order></author><author><firstname>Hans J.</firstname><surname>Hammers</surname><order>4</order></author><author><firstname>Sandhya</firstname><surname>Srinivas</surname><order>5</order></author><author><firstname>Scott S.</firstname><surname>Tykodi</surname><order>6</order></author><author><firstname>Jeffrey A.</firstname><surname>Sosman</surname><order>7</order></author><author><firstname>Elizabeth R.</firstname><surname>Plimack</surname><order>8</order></author><author><firstname>Giuseppe</firstname><surname>Procopio</surname><order>9</order></author><author><firstname>David F.</firstname><surname>McDermott</surname><order>10</order></author><author><firstname>Daniel</firstname><surname>Castellano</surname><order>11</order></author><author><firstname>Toni K.</firstname><surname>Choueiri</surname><order>12</order></author><author><firstname>Frede</firstname><surname>Donskov</surname><order>13</order></author><author><firstname>Howard</firstname><surname>Gurney</surname><order>14</order></author><author><firstname>Stéphane</firstname><surname>Oudard</surname><order>15</order></author><author><firstname>Martin</firstname><surname>Richardet</surname><order>16</order></author><author><firstname>Katriina</firstname><surname>Peltola</surname><order>17</order></author><author><firstname>Ajjai S.</firstname><surname>Alva</surname><order>18</order></author><author><firstname>Michael</firstname><surname>Carducci</surname><order>19</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>20</order></author><author><firstname>Christine</firstname><surname>Chevreau</surname><order>21</order></author><author><firstname>Satoshi</firstname><surname>Fukasawa</surname><order>22</order></author><author><firstname>Yoshihiko</firstname><surname>Tomita</surname><order>23</order></author><author><firstname>Thomas C.</firstname><surname>Gauler</surname><order>24</order></author><author><firstname>Christian K.</firstname><surname>Kollmannsberger</surname><order>25</order></author><author><firstname>Fabio A.</firstname><surname>Schutz</surname><order>26</order></author><author><firstname>James</firstname><surname>Larkin</surname><order>27</order></author><author><firstname>David</firstname><surname>Cella</surname><order>28</order></author><author><firstname>M. Brent</firstname><surname>McHenry</surname><order>29</order></author><author><firstname>Shruti Shally</firstname><surname>Saggi</surname><order>30</order></author><author><firstname>Nizar M.</firstname><surname>Tannir</surname><order>31</order></author></authors><documents/><OutputDurs/></rfc1807> |
| spelling |
2020-11-11T16:48:39.1648073 v2 55409 2020-10-13 Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2020-10-13 SGMED Journal Article Cancer 126 18 4156 4167 Wiley 0008-543X 1097-0142 15 9 2020 2020-09-15 10.1002/cncr.33033 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2020-11-11T16:48:39.1648073 2020-10-13T12:21:45.2061165 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Robert J. Motzer 1 Bernard Escudier 2 Saby George 3 Hans J. Hammers 4 Sandhya Srinivas 5 Scott S. Tykodi 6 Jeffrey A. Sosman 7 Elizabeth R. Plimack 8 Giuseppe Procopio 9 David F. McDermott 10 Daniel Castellano 11 Toni K. Choueiri 12 Frede Donskov 13 Howard Gurney 14 Stéphane Oudard 15 Martin Richardet 16 Katriina Peltola 17 Ajjai S. Alva 18 Michael Carducci 19 John Wagstaff 20 Christine Chevreau 21 Satoshi Fukasawa 22 Yoshihiko Tomita 23 Thomas C. Gauler 24 Christian K. Kollmannsberger 25 Fabio A. Schutz 26 James Larkin 27 David Cella 28 M. Brent McHenry 29 Shruti Shally Saggi 30 Nizar M. Tannir 31 |
| title |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| spellingShingle |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial John Wagstaff |
| title_short |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| title_full |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| title_fullStr |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| title_full_unstemmed |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| title_sort |
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial |
| author_id_str_mv |
fdab5e9e2fe06c93d3ffa19c816bdcf6 |
| author_id_fullname_str_mv |
fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff |
| author |
John Wagstaff |
| author2 |
Robert J. Motzer Bernard Escudier Saby George Hans J. Hammers Sandhya Srinivas Scott S. Tykodi Jeffrey A. Sosman Elizabeth R. Plimack Giuseppe Procopio David F. McDermott Daniel Castellano Toni K. Choueiri Frede Donskov Howard Gurney Stéphane Oudard Martin Richardet Katriina Peltola Ajjai S. Alva Michael Carducci John Wagstaff Christine Chevreau Satoshi Fukasawa Yoshihiko Tomita Thomas C. Gauler Christian K. Kollmannsberger Fabio A. Schutz James Larkin David Cella M. Brent McHenry Shruti Shally Saggi Nizar M. Tannir |
| format |
Journal article |
| container_title |
Cancer |
| container_volume |
126 |
| container_issue |
18 |
| container_start_page |
4156 |
| publishDate |
2020 |
| institution |
Swansea University |
| issn |
0008-543X 1097-0142 |
| doi_str_mv |
10.1002/cncr.33033 |
| publisher |
Wiley |
| college_str |
Faculty of Medicine, Health and Life Sciences |
| hierarchytype |
|
| hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
| hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
| department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
| document_store_str |
0 |
| active_str |
0 |
| published_date |
2020-09-15T04:09:36Z |
| _version_ |
1763753670494650368 |
| score |
11.013148 |